Adverse Events Module

Adverse Events Module

For researchers submitting trial data to ClinicalTrials.gov, the Adverse Events module is one of four mandatory results sections. It requires reporting in three primary categories: All-Cause Mortality: A table tracking all deaths that occurred during the study, regardless of cause. Serious Adverse Events (SAEs): A tabular summary of events resulting in death, life-threatening conditions, hospitalization, or significant disability. Other Adverse Events: A table for non-serious events that exceed a specific frequency threshold, such as 5% within any study arm.

Adverse Events Module path is as follows:

Study -> Results Section -> Adverse Events Module -> Event Groups

Study -> Results Section -> Adverse Events Module -> Serious Events

Study -> Results Section -> Adverse Events Module -> Other Events

Adverse Events Module


Ignite Creation Date: 2025-12-25 @ 2:16 AM
Ignite Modification Date: 2025-12-26 @ 12:46 AM
NCT ID: NCT05305560
Description: Adverse events were collected passively upon Participant declaration.
Frequency Threshold: 0
Time Frame: 56 days
Study: NCT05305560
Study Brief: A Study to Evaluate the Efficacy and Safety of Ivermectin in COVID-19 Prevention
Event Groups(If Any):

Event Groups

Title Description Deaths # Affected Deaths # At Risk Serious # Affected Serious # At Risk Other # Affected Other # At Risk View
Placebo Matching placebo tablets: Daily placebo tablets intake for 28 days 0 None 0 199 109 199 View
Active IMP Ivermectin Tablets: Daily ivermectin tablets intake for 28 days ; 200 mcg/kg on D1 then 100 mcg/kg daily from D2 to D28. 0 None 0 200 49 200 View
Serious Events(If Any):
Other Events(If Any):

Other Events

Term Type Organ System Vocab View
COVID-19 SYSTEMATIC_ASSESSMENT Infections and infestations MedDRA (Unspecified) View
Hyperlipidemia NON_SYSTEMATIC_ASSESSMENT Metabolism and nutrition disorders MedDRA (Unspecified) View
Headache NON_SYSTEMATIC_ASSESSMENT Nervous system disorders MedDRA (Unspecified) View
Palpitations NON_SYSTEMATIC_ASSESSMENT Cardiac disorders MedDRA (Unspecified) View
Dysmenorrhea NON_SYSTEMATIC_ASSESSMENT Reproductive system and breast disorders MedDRA (Unspecified) View
Fatigue NON_SYSTEMATIC_ASSESSMENT General disorders MedDRA (Unspecified) View
Basophil count increased NON_SYSTEMATIC_ASSESSMENT Investigations MedDRA (Unspecified) View
Dizziness NON_SYSTEMATIC_ASSESSMENT Nervous system disorders MedDRA (Unspecified) View
Vertigp NON_SYSTEMATIC_ASSESSMENT Ear and labyrinth disorders MedDRA (Unspecified) View
Diarrhoea NON_SYSTEMATIC_ASSESSMENT Gastrointestinal disorders MedDRA (Unspecified) View
Nausea NON_SYSTEMATIC_ASSESSMENT Gastrointestinal disorders MedDRA (Unspecified) View
Muscle spasms NON_SYSTEMATIC_ASSESSMENT Musculoskeletal and connective tissue disorders MedDRA (Unspecified) View
Alanine aminotransferase increased NON_SYSTEMATIC_ASSESSMENT Investigations MedDRA (Unspecified) View
Aspartate aminotransferase increased NON_SYSTEMATIC_ASSESSMENT Investigations MedDRA (Unspecified) View
Body temperature increased NON_SYSTEMATIC_ASSESSMENT Investigations MedDRA (Unspecified) View
C-reactive protein increased NON_SYSTEMATIC_ASSESSMENT Investigations MedDRA (Unspecified) View